TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9435408

Group type: COMPARATOR
Intervention: Raloxifene (400 mg) for 5 days in any phase of the menstrual cycle
Number of subjects: 31

Group type: COMPARATOR
Intervention: Raloxifene (100 or 200 mg) for 28 days starting on day 3 of the cycle
Number of subjects: 31
Study: 8072187

Group type: COMPARATOR
Intervention: Fosfomycin (FOM) plus cefmetazole (CMZ)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Fosfomycin (FOM) plus flomoxef (FMOX)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Arbekacin (ABK) plus ceftazidime (CAZ) or ABK plus piperacillin (PIPC)
Number of subjects: 54
Study: 3377925

Group type: EXPERIMENTAL
Intervention: Extradural analgesia S5‐T4
Number of subjects: 16

Group type: COMPARATOR
Intervention: Neuroleptanaesthesia (NLA)
Number of subjects: 16
Study: 12142560

Group type: EXPERIMENTAL
Intervention: High-dose interleukin-2 (HD IL-2)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Corticosteroids and plasmapheresis
Number of subjects: 1
Study: 31913191

Group type: EXPERIMENTAL
Intervention: Needle-Knife Fistulotomy (NKF)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Conventional Cannulation Method (CCM)
Number of subjects: 207
Study: 29037926

Group type: EXPERIMENTAL
Intervention: Reduction clamp
Number of subjects: 85

Group type: COMPARATOR
Intervention: Manual manipulation
Number of subjects: 85
Study: 26968631

Group type: EXPERIMENTAL
Intervention: Brief Negotiated Interviewing intervention
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 200
Study: 24219343

Group type: EXPERIMENTAL
Intervention: Writing down the request for help on a request card
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard consultation without request card
Number of subjects: 0
Study: 22955099

Group type: EXPERIMENTAL
Intervention: Informal discussion
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Discussion plus information
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Brief motivational interview plus information
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Action stage of readiness to change
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Higher education
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Higher levels of depression
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Memory and executive function, heavy preinjury alcohol use
Number of subjects: 60
Study: 20207666

Group type: EXPERIMENTAL
Intervention: Exposure to food temptations (pictures of food and real food)
Number of subjects: 0
Study: 18533940

Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (13vPnC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 23-valent plain polysaccharide pneumococcal vaccine (23vPn)
Number of subjects: 30
Study: 15983186

Group type: EXPERIMENTAL
Intervention: Geriatric inpatient care
Number of subjects: 99

Group type: COMPARATOR
Intervention: Geriatric outpatient care
Number of subjects: 99

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 99
Study: 12182217

Group type: EXPERIMENTAL
Intervention: Simulated weightlessness (supine body position)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (pre-oxygenated for 60 min, first 10 min exercising)
Number of subjects: 65
Study: 10485075

Group type: EXPERIMENTAL
Intervention: Manganese-DPDP
Number of subjects: 15

Group type: COMPARATOR
Intervention: Gadolinium-DTPA
Number of subjects: 15
Study: 8698787

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Epsilon aminocaproic acid
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 1750603

Group type: EXPERIMENTAL
Intervention: 5 mg intramuscular diamorphine
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5 mg epidural diamorphine
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2.5 mg epidural diamorphine
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5 mg epidural diamorphine with adrenaline 1/200,000
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2.5 mg epidural diamorphine with adrenaline 1/200,000
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epidural diamorphine with adrenaline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5 mg epidural diamorphine with adrenaline vs 2.5 mg with adrenaline
Number of subjects: 0
Study: 7067925

Group type: EXPERIMENTAL
Intervention: Tinidazole 2 g single dose
Number of subjects: 100

Group type: COMPARATOR
Intervention: Metronidazole 2 g single dose
Number of subjects: 100
Study: 30450545

Group type: EXPERIMENTAL
Intervention: Fremanezumab 225 mg
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Fremanezumab 675 mg
Number of subjects: 297
Study: 30127007

Group type: COMPARATOR
Intervention: CYD‐TDV vaccine
Number of subjects: 2
Study: 28768076

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen at 1.5 ATA
Number of subjects: 132

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen at 2.0 ATA
Number of subjects: 132

Group type: COMPARATOR
Intervention: Local care
Number of subjects: 132

Group type: COMPARATOR
Intervention: Sham treatment (HOPPS study)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen at 1.5 ATA (HOPPS study)
Number of subjects: 132
Study: 23744292

Group type: EXPERIMENTAL
Intervention: Peer navigation intervention
Number of subjects: 24

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 24
Study: 22353604

Group type: EXPERIMENTAL
Intervention: i.v. ferric carboxymaltose and subcutaneous erythropoietin (EPOFE arm)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: i.v. ferric carboxymaltose (FE arm)
Number of subjects: 306

Group type: COMPARATOR
Intervention: i.v. placebo and subcutaneous placebo (PLACEBO arm)
Number of subjects: 306
Study: 19645851

Group type: EXPERIMENTAL
Intervention: silver-loaded seaweed fiber T-shirts
Number of subjects: 37

Group type: COMPARATOR
Intervention: cotton T-shirts
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: silver-loaded seaweed fiber T-shirts and cotton T-shirts
Number of subjects: 37
Study: 17624477

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (500 units)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 15823861

Group type: EXPERIMENTAL
Intervention: Statin + ASA (Group A)
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Statin (Group B)
Number of subjects: 1600

Group type: COMPARATOR
Intervention: ASA (Group C)
Number of subjects: 1600

Group type: COMPARATOR
Intervention: No statin, no ASA (Group D)
Number of subjects: 1600
Study: 12066485

Group type: EXPERIMENTAL
Intervention: Randomized controlled trials (RCTs) in prosthodontics
Number of subjects: 92
Study: 9607867

Group type: EXPERIMENTAL
Intervention: Primaquine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unvaccinated control group
Number of subjects: 0
Study: 7635993

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Fluoxetine 40 mg/day
Number of subjects: 249

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day and Methadone 65-80 mg
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Two visits/week
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Five visits/week
Number of subjects: 249
Study: 2693560

Group type: EXPERIMENTAL
Intervention: Filled bladder
Number of subjects: 142

Group type: COMPARATOR
Intervention: Empty bladder
Number of subjects: 142
Study: 576779

Group type: EXPERIMENTAL
Intervention: Intensive physiotherapy
Number of subjects: 56

Group type: COMPARATOR
Intervention: Routine physiotherapy
Number of subjects: 56
Study: 31219591

Group type: EXPERIMENTAL
Intervention: Assessment of ACGD symptoms and molecular analysis of 'Candidatus Liberibacter africanus' (CLaf)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Molecular characterization of pathogens
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Detection of Candidatus Liberibacter asiaticus
Number of subjects: 105
Study: 28631208

Group type: EXPERIMENTAL
Intervention: Modified Blalock‐Taussig shunt (MBTS)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Right ventricle‐to‐pulmonary artery shunt (RVPAS)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Post‐Norwood
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Pre‐stage II
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: 14 months
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Overall PVF patterns
Number of subjects: 261
Study: 26508834

Group type: EXPERIMENTAL
Intervention: Urinary kallidinogenase (UK) + conventional treatment
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 90
Study: 23846872

Group type: EXPERIMENTAL
Intervention: CYP2B6*1/*1 genotype
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CYP2B6*6 allele
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Expressed CYP2B6 proteins
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CYP2B6*6/*6 genotype
Number of subjects: 20
Study: 21598901

Group type: EXPERIMENTAL
Intervention: Unilateral pedicle screw fixation and bilateral decompression via 1-sided paramedian approach (Group 1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bilateral pedicle screw fixation and bilateral decompression via bilateral paramedian approach (Group 2)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both groups (Group 1 and Group 2)
Number of subjects: 40
Study: 19420398

Group type: EXPERIMENTAL
Intervention: Physical activity homework (30 minutes, 3 days a week for 12 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No homework
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physical activity homework
Number of subjects: 0
Study: 16534040

Group type: EXPERIMENTAL
Intervention: Telephone care (n = 417)
Number of subjects: 837

Group type: COMPARATOR
Intervention: Standard care (n = 420)
Number of subjects: 837
Study: 12753341

Group type: EXPERIMENTAL
Intervention: IFN-alpha2b alone for 48 weeks (R1: 42 patients)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: IFN-alpha2b plus ribavirin (600 mg/day) for 24 weeks and IFN-alpha2b alone for the next 24 weeks (R2: 48 patients)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: IFN-alpha2b plus ribavirin for 24 weeks and then IFN-alpha2b alone for the next 24 weeks (R3: 104 patients)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: IFN-alpha2b plus ribavirin for 48 weeks (R4: 103 patients)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Ribavirin dose below 10.6 mg/kg/day
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Ribavirin dose over 10.6 mg/kg/day
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 297
Study: 10671847

Group type: EXPERIMENTAL
Intervention: Clonidine 150 microg
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Clonidine 300 microg
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 62
Study: 9187104

Group type: EXPERIMENTAL
Intervention: Vorozole (2.5 mg once daily for 7 days)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (untreated postmenopausal breast cancer patients, N=9)
Number of subjects: 11
Study: 8126259

Group type: EXPERIMENTAL
Intervention: Norfloxacin with milk
Number of subjects: 6

Group type: COMPARATOR
Intervention: Norfloxacin with water
Number of subjects: 6
Study: 2880069

Group type: EXPERIMENTAL
Intervention: BN 52063 (80 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: BN 52063 (120 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: BN 52063 (80 mg and 120 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: BN 52063 (in vitro)
Number of subjects: 6

Group type: COMPARATOR
Intervention: ADP (in vitro)
Number of subjects: 6
Study: 30638635

Group type: EXPERIMENTAL
Intervention: Digital lifestyle intervention (website, Fitbit One, text messaging)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control arm (no intervention)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Intervention arm
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Intervention participants
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Exploratory outcomes
Number of subjects: 76
Study: 30597865

Group type: EXPERIMENTAL
Intervention: High protein diet (PROHIGH: 2.9 g·kg−1·d−1)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Moderate protein diet (PROMOD: 1.8 g·kg−1·d−1)
Number of subjects: 16
Study: 26789541

Group type: EXPERIMENTAL
Intervention: 4 mg silodosin once daily for 4 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: 0.2 mg tamsulosin once daily for 4 weeks
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: silodosin
Number of subjects: 34

Group type: COMPARATOR
Intervention: tamsulosin
Number of subjects: 34
Study: 24253615

Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg
Number of subjects: 83

Group type: COMPARATOR
Intervention: Amlodipine 5 mg
Number of subjects: 83
Study: 22111894

Group type: EXPERIMENTAL
Intervention: London Stroke Carer Training Course
Number of subjects: 900

Group type: COMPARATOR
Intervention: Usual care according to national guidelines
Number of subjects: 900
Study: 19998527

Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 0
Study: 17804327

Group type: EXPERIMENTAL
Intervention: Fiber posts with porcelain fused to metal crowns
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fiber posts with lithium disilicate crowns
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fiber posts with fiber‐reinforced composite crowns
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fiber posts with zirconia crowns
Number of subjects: 80

Group type: COMPARATOR
Intervention: Without fiber posts with porcelain fused to metal crowns
Number of subjects: 80

Group type: COMPARATOR
Intervention: Without fiber posts with lithium disilicate crowns
Number of subjects: 80

Group type: COMPARATOR
Intervention: Without fiber posts with fiber‐reinforced composite crowns
Number of subjects: 80

Group type: COMPARATOR
Intervention: Without fiber posts with zirconia crowns
Number of subjects: 80
Study: 15086358

Group type: EXPERIMENTAL
Intervention: dopexamine 1 microg x kg(‐1) min(‐1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: dopexamine 3 microg x kg(‐1) min(‐1)
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo (NaCl 0.9%)
Number of subjects: 12
Study: 11020505

Group type: EXPERIMENTAL
Intervention: Blastomere biopsy followed by blastomere nucleus conversion into metaphase chromosomes
Number of subjects: 19
Study: 8636880

Group type: EXPERIMENTAL
Intervention: Facial expressions of anger
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Facial expressions of fear
Number of subjects: 22
Study: 1314260

Group type: COMPARATOR
Intervention: Propranolol 120 mg/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pindolol 15 mg/day
Number of subjects: 20
Study: 4043678

Group type: EXPERIMENTAL
Intervention: Clonidine 0.3 mg
Number of subjects: 8
Study: 3715441

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg nocte
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg b.d.
Number of subjects: 97
Study: 31525334

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 80

Group type: COMPARATOR
Intervention: Noninsertive Sham Acupuncture
Number of subjects: 80
Study: 30064923

Group type: EXPERIMENTAL
Intervention: History of psoriasis
Number of subjects: 1563

Group type: COMPARATOR
Intervention: No history of psoriasis (Control)
Number of subjects: 1563
Study: 28923035

Group type: EXPERIMENTAL
Intervention: Functional position cast immobilization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Volar flexion-ulnar deviation position cast immobilization
Number of subjects: 0
Study: 26026400

Group type: EXPERIMENTAL
Intervention: Performance-Based Financing (PBF)
Number of subjects: 157
Study: 23928836

Group type: EXPERIMENTAL
Intervention: Doxycycline (20 mg orally, twice a day for at least 2 days prior to surgery, on the day of surgery, and for the first 3 postoperative days)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 42
Study: 20189916

Group type: EXPERIMENTAL
Intervention: Brief psychosocial intervention using CD‐ROM (BPIC)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 71
Study: 18345369

Group type: EXPERIMENTAL
Intervention: Telephone based asthma management (six telephone calls over 6 months)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 71
Study: 16550952

Group type: EXPERIMENTAL
Intervention: Algosteril
Number of subjects: 50

Group type: COMPARATOR
Intervention: Polyvinyl acetal (Merocel)
Number of subjects: 50
Study: 14711068

Group type: EXPERIMENTAL
Intervention: Detailed initial assessment including obesity-focused history, physical examination, and selected laboratory and diagnostic tests
Number of subjects: 0
Study: 10867543

Group type: EXPERIMENTAL
Intervention: HDhep (heparin anticoagulation)
Number of subjects: 10

Group type: COMPARATOR
Intervention: HDcit (trisodium citrate anticoagulation)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combined data for HDhep and HDcit
Number of subjects: 10
Study: 9327192

Group type: EXPERIMENTAL
Intervention: Sulodexide (250 lipoproteinlipase releasing units, two capsules twice daily for 176 days on average)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Pentoxifylline (400 mg tablets, one tablet three times a day for 180 days on average)
Number of subjects: 107
Study: 7900387

Group type: EXPERIMENTAL
Intervention: Immunomodulation with Poly-A Poly-U
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no immunomodulation)
Number of subjects: 50
Study: 3710287

Group type: EXPERIMENTAL
Intervention: Vaginal therapy with 500 mg metronidazole once a day for 7 days
Number of subjects: 38

Group type: COMPARATOR
Intervention: Oral therapy with 400 mg metronidazole twice daily for 7 days
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Vaginal therapy
Number of subjects: 38

Group type: COMPARATOR
Intervention: Oral therapy
Number of subjects: 38
Study: 29684433

Group type: EXPERIMENTAL
Intervention: Titrated oxygen (initially 2 L/min, later adjusted to 4 L/min if tolerated)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control oxygen (>10 L/min)
Number of subjects: 61
Study: 27821114

Group type: EXPERIMENTAL
Intervention: Bright light therapy (9,000 lux)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Dim red light therapy (100 lux)
Number of subjects: 150
Study: 24326079

Group type: EXPERIMENTAL
Intervention: Wisdom nominees
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 94
Study: 22324528

Group type: EXPERIMENTAL
Intervention: Training set with 70% abnormal cases
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Training set with 50% abnormal cases
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Training set with 30% abnormal cases
Number of subjects: 100
Study: 20430138

Group type: EXPERIMENTAL
Intervention: Dietary education using Australia's National Heart Foundation Tick symbol
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Dietary education using Food Standards Australia and New Zealand's low-salt guideline of 120 mg sodium/100 g food
Number of subjects: 49
Study: 18540778

Group type: EXPERIMENTAL
Intervention: Secretin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 15935269

Group type: EXPERIMENTAL
Intervention: Conventional glass ionomer cement (GIC-Ketac-Fil)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Resin-modified GIC (RM-GIC-Vitremer)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Composite resin (CR-Z250) (negative control)
Number of subjects: 8
Study: 12966258

Group type: EXPERIMENTAL
Intervention: 0.5mg/kg ketamine administered epidurally (Kepi group)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg ketamine administered intravenously (Kiv group)
Number of subjects: 45

Group type: COMPARATOR
Intervention: 10ml normal saline administered epidurally (Ctr group)
Number of subjects: 45
Study: 11339006

Group type: EXPERIMENTAL
Intervention: Young runners (age 20-24)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Old runners (age 52.9)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (healthy volunteers aged 21.6)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (men aged 52.9)
Number of subjects: 20
Study: 8772558

Group type: EXPERIMENTAL
Intervention: Alendronate (40 mg daily for 6 months)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Etidronate (400 mg daily for 6 months)
Number of subjects: 89
Study: 1334248

Group type: EXPERIMENTAL
Intervention: 50 g daily of oatbran
Number of subjects: 29

Group type: COMPARATOR
Intervention: Oat-free control diet
Number of subjects: 29
Study: 6397334

Group type: EXPERIMENTAL
Intervention: 200 mg pivmecillinam plus 250 mg pivampicillin twice daily for 5 days
Number of subjects: 58

Group type: COMPARATOR
Intervention: 250 mg amoxycillin plus 125 mg clavulanate 3-times daily for 5 days
Number of subjects: 58
Study: 31741955

Group type: EXPERIMENTAL
Intervention: Coblation tonsillectomy
Number of subjects: 1004

Group type: COMPARATOR
Intervention: Conventional tonsillectomy
Number of subjects: 1004
Study: 28973115

Group type: EXPERIMENTAL
Intervention: Gamification intervention
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 200
Study: 26791606

Group type: EXPERIMENTAL
Intervention: Cryolipolysis and diet
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Laser lipolysis and diet
Number of subjects: 45

Group type: COMPARATOR
Intervention: Only diet
Number of subjects: 45
Study: 25082132

Group type: EXPERIMENTAL
Intervention: Steering Teens Safe intervention (45-minute session, four follow-up phone sessions, DVD, workbook)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Steering Teens Safe intervention
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Steering Teens Safe intervention (successful communication)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control (standard brochure about safe driving)
Number of subjects: 145
Study: 22051103

Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 374

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 374